Interface Clinical Research has identified thousands of suitable patients for sponsors in feasibility studies for type 2 diabetes and chronic kidney disease (CKD).

Interface was able to identify these patients from four of their GP practice sites across the UK in only a matter of days.

Offering a new model for running primary care trials, Interface works in partnership with GP practices across the UK to deliver large numbers of suitable patients for Phase III and IV clinical trials. The large numbers of suitable patients that Interface has found in these feasibility studies demonstrates the impressive patient recruitment capabilities of their model.

Interface was able to find more than 2500 patients who met the inclusion criteria for a large type 2 diabetes study from a total list of 44,859 patients.

There are more than 2.9 million people living with diabetes in the UK today and this number is predicted to exceed 5 million by 2025. For the chronic kidney disease (CKD) study, Interface was able to find 585 patients who met the inclusion criteria for the trial from a total list of 44,859 patients.

CKD is a general term used to indicate that a patient’s kidneys are damaged, diseased or not functioning properly. Around one in eight people will develop CKD in their lifetime.

Interface’s clinical trial model is based on working with large GP practices across the UK to run Phase III and IV clinical trials using the existing practice facilities, and recruiting local patients from the practice’s existing patient database.

Interface has already identified more than 40 GP practices and larger healthcare organisations, which work in a hub and spoke model with adjacent practices, to become involved in running clinical trials.

Interface’s investigators run the clinical trials at the GP practice to ensure that patients are seen punctually, and are given adequate time, by experienced investigators.

Patients are recruited for clinical trials following a sophisticated database screen, done by Interface’s investigators, which can accurately identify the most suitable patients.

This tailored approach to patient recruitment means that far fewer patients will fail the screening for clinical trials. Interface’s advanced patient retention system has been developed by its sister company Interface Clinical Services, which has run hundreds of patient clinics in GP practices during the past 10 years.

Interface’s model offers considerable advantages compared with traditional ways of recruiting and running trials, using dedicated research centres and individual GPs.

The fixed cost of the dedicated research centre is becoming a major barrier to offering a competitive service, particularly as they have limited access to large patient databases and suffer from large numbers of patient dropouts.

The individual GP model has always been inefficient; on average, GPs typically only recruit five patients per trial, and often lose patients because of their heavy workload, which results in study participants having appointments delayed or cancelled, a fact that obviously contributes to the dropout rate.